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NUCLEIC ACIDS ENCODING SARC0C YSTIS
NE URONA ANTIGEN AND USES THEREOF

Improved assays based on simpli?ed, and thus more reliable,
techniques that are more appropriate for diagnostic use.
Nucleic acid ampli?cation assays (polymerase chain reac
tion; PCR) for S. neurona detection have been developed

The present application is a continuation of US. utility
patent application Ser. No. 11/445,045, ?led on Jun. 1, 2006

based on the S. neurona ribosomal RNA genes (Fenger et al.,

now US. Pat. No. 7,256,282, Which in turn claims priority to

1994; Marsh et al., 1996). These PCR-based assays detect the

US. utility patent application Ser. No. 10/369,430, ?led on
Feb. 19, 2003, Which claims the bene?t of priority of US.

presence of S. neurona DNA, and therefore the parasite, in the
horse, so they can provide a de?nitive indication of active

provisional patent application No. 60/357,479, ?led Feb. 15,

infection. HoWever, prior to the present invention, these
nucleic acid-based tests have been inherently unreliable. Spe

2002, the disclosures of each of Which are incorporated herein

ci?cally, parasites may be very feW or non-existent in a CSF
sample, so there Will be feW or no available target molecules

in their entirety by reference.

(i.e., parasite genomic DNA) for PCR ampli?cation. More

TECHNICAL FIELD

importantly, the general use of PCR for diagnosis is still
suspect. Although measures can be taken to improve the

The present invention relates to nucleic acids of Sarcocys

reliability of PCR, the technique continues to be troubled by
both false positive and false negative results.

Zis neurona. In particular, the present invention relates to
nucleic acids of Sarcocyslis neurona and to nucleic acid
reagents and antibodies for use in methods of detection and

prevention of Sarcocyslis neurona infection. More particu
larly, the present invention relates to novel nucleic acid

The selection of an antigen for development of a diagnostic
test can be someWhat subjective since any particularpathogen
20

antibody response in the infected animal. In this regard, sur
face antigens of the Coccidia, such as the primary surface

including primers, probes, antigen/antibody diagnostic kits,
vectors for production of peptides encoding the novel nucleic
acids, and to antigenic proteins and vaccines against Sarco
cyslis neurona.

antigens of Toxoplasma gondii (Handman and Remington,
25

(SRSs). Signi?cantly, the TgSAGl surface antigen of T gon
dii has been shoWn to protect mice against acute toxoplasmo

Sarcocyslis neurona is an apicomplexan parasite that is the

sis (BuloW and Boothroyd, 1991), and the NcSAGl (p29)

primary cause of equine protoZoal myeloencephalitis (EPM;

major surface antigen of N. caninum has been used to develop
an ELISA for detection ofNeospora infection in cattle (Howe

Dubey et al., 1991), Which is a common and debilitating
infectious disease that affects the central nervous system of
horses. S. neurona is related to the human and animal patho

gen Toxoplasma gondii and to the important veterinary patho

1980; Sharma et al., 11983) and Neospora caninum (HoWe et
al., 1998), are exceedingly immunogenic. These surface anti
gens have been designated SAGs and SAG-related sequences

BACKGROUND OF THE INVENTION

gen Neospora spp. The geographic range of S. neurona
appears to be limited to the Western hemisphere, thus EPM
primarily affects horses in the Americas.
De?nitive antemortem diagnosis of EPM remains exceed
ingly dif?cult, for a variety of reasons. Horses af?icted With

is composed of numerous antigenic proteins. Logically, the
target molecule in a diagnostic assay must elicit a detectable

sequences of Sarcocyslis neurona and to utiliZation thereof

et al., 2002). Collectively, these previous studies demonstrate
that coccidian SAGs are at least candidate proteins for the
35

development of both diagnostic assays and protective vac
cines.

Despite the foregoing art, prior to the present invention it
had not been shoWn that the surface antigens of S. neurona

(i.e., SnSAG2, SnSAG3, and SnSAG4) are effective target
40

EPM exhibit signs that are similar to a number of different

molecules for examining immune responses in infected

horses and for developing improved assays for EPM diagno

neurological disorders (MacKay et al., 2000). Furthermore,

sis. Such molecules Would also provide the basis for

S. neurona infection does not equate to disease, since only a

improved vaccines and diagnostic kits, including antigen and

small proportion of seropositive horses Will suffer from EPM
(MacKay et al., 2000); as a consequence, the detection of
anti-S. neurona antibodies in serum provides little diagnostic

45

information other than indicating previous exposure to the

parasite. Analysis of cerebrospinal ?uid (CSF) to reveal
intrathecal antibody production has improved the predictive
value of antibody detection for EPM diagnosis. HoWever,

SUMMARY OF THE INVENTION

50

interpretation of CSF antibody presence can be confounded
by contamination of the CSF sample With minute amounts of
serum antibodies (Miller et al., 1999).

The present invention satis?es the aforementioned need in
the art by providing a novel isolated nucleic acid encoding an
antigenic protein derived from Sarcocyslis neurona, or a

unique fragment thereof. In one embodiment, the invention
provides novel isolated nucleic acids encoding membrane
associated polypeptides SnSAG2, SnSAG3, and SnSAG 4.

Other contemporary diagnostic assays provide only
mediocre predictive value for EPM diagnosis. Western blot
analysis (a.k.a., immunoblot) of crude S. neurona lysate
remains the principal immunodiagnostic test that is used to
detect antibodies in suspect EPM horses (Granstrom et al.,
1993). The assay relies on the recognition of several antigens,
primarily in the loW molecular Weight range, by serum/CSF
antibodies (Dubey et al., 2001b; Granstrom et al., 1993;

antibody kits, for fast and reliable diagnosis of S. neurona
infection.

55

The present invention also provides puri?ed antigenic
polypeptide fragments encoded by the novel nucleic acid
sequences set forth herein that encode for Sarcocyslis neu
rona. In one embodiment, the invention provides puri?ed

antigenic proteins or puri?ed antigenic polypeptide frag
60

ments encoded by the novel nucleic acid sequences set forth
herein that encode for SnSAG2, SnSAG3, and SnSAG4. In

another embodiment, the present invention provides a puri

MacKay et al., 2000). Unfortunately, Western blot analysis is
primarily a research tool that is relatively laborious and some

?ed antigenic polypeptide fragment encoded by the nucleic

What hindered by subjectivity, so any improvements to the

acid sequences set forth herein or a selective portion thereof

immunoblot are of limited value. While the immunoblot has

been utiliZed for a number of years to help diagnose EPM, it
is a ?rst-generation test that needs to be replaced With

65

in a pharmaceutically acceptable carrier.
The present invention also provides isolated nucleic acids
capable of selectively hybridizing With the nucleic acid from

US 7,524,946 B2
3

4

Sarcocyslis neurona including, but not limited to, primers and

typical tWo-domain apicomplexan SAG. SnSAG2 Will also
align With the carboxyl-terminal domain of the TgSAGs.

probes for utilization in polymerase chain reaction (PCR) and
other nucleic acid ampli?cation techniques. The isolated

FIG. 3 shoWs a Western blot analysis of the SnSAGs in S.
neurona meroZoites. The SnSAG genes Were expressed in E.

nucleic acids of the present invention are capable of hybrid

iZing under conditions of loW, moderate, and high stringency

coli, and monospeci?c polyclonal antisera Were generated
against the recombinant proteins. Western blot analysis of
reduced antigen revealed that each SnSAG migrated signi?
cantly higher than its predicted molecular Weight, consistent

With a nucleic acid from Sarcocyslis neurona.

Further, the present invention provides vectors comprising
the isolated nucleic acids, or degenerate variants thereof, set
forth herein encoding Sarcocyslis neurona or a unique frag
ment thereof and provides the vector in a host capable of

With What has been observed for the T gondii SAGs/SRS.
SnSAG1 and SnSAG4 co-migrated and corresponded to the
immunodominant band at about 30-32 kDa. SnSAG2 corre

expressing the polypeptide encoded by that nucleic acid.
Still yet further, the present invention also provides a puri

sponded to an immunodominant band at approximately 18-20
kDa.

?ed polyclonal and or a monoclonal antibody speci?cally

FIG. 4 shoWs the SnSAGs are membrane-associated in

reactive With Sarcocyslis neurona and a method of detection

Sarcocyslis neurona meroZites. Triton X-114 partitioning

of Sarcocyslis neurona utiliZing the antibodies of the present
invention.

assays indicated that the SnSAGs are associated With mem

branes, consistent With their surface localiZation via gly

The above-described embodiments provided by the
present invention, provide a method for detecting Sarcocyslis
neurona in a biological sample, comprising detecting the

colipid anchoring. Western blot analysis of the partitioned
proteins With the SnSAG-speci?c polyclonal antisera
revealed that all four SnSAGs Were separated exclusively into

presence in the sample of an antibody or fragment thereof
Which speci?cally binds to a polypeptide comprising an iso
lated amino acid sequence selected from the group set forth in

the detergent phase (D). The control protein, SnMIClO, Was
partitioned into the aqueous phase (A), as expected.
FIG. 5 shoWs that the four SnSAGs are displayed on the

the Sequence Listing as SEQ ID NO.: 24, SEQ ID NO: 26,
and SEQ ID NO: 28. In one embodiment of the method, the

biological sample is serum. In another embodiment, the

surface of Sarcocyslis neurona meroZoites. Surface biotiny
25

present invention provides a method as described for detect

blot analysis With the SnSAG-speci?c antisera revealed each
of the SnSAGs in the biotinylated protein fraction precipi

ing Sarcocyslis neurona in cerebrospinal ?uid (CSF).
Finally, the present invention provides a kit for detecting
Sarcocyslis neurona in a biological sample, comprising at
least one isolated amino acid sequence selected from the

tated With immobiliZed streptavidin. The SnSAGs Were not
30

group set forth in the Sequence Listing as SEQ ID NO.: 24,
SEQ ID NO: 26, and SEQ ID NO: 28, and a reporter molecule
for detecting a ?rst antibody or fragment thereof Which spe
ci?cally binds to a polypeptide comprising the at least one
isolated amino acid sequence. The reporter molecule may be
any suitable detectable second antibody or fragment thereof
Which binds to the ?rst antibody or fragment thereof, and

35

Which is labeled With a detectable moiety or bound to a

substrate.

lation of S. neurona meroZoites indicated that the four
SnSAGs are displayed on the surface of the parasite. Western

40

present in the non-labeled parasites, thus indicating that the
streptavidin precipitation Were speci?c for biotin-labeled
proteins. The negative control protein (actin) Was not detected
in the biotin-labeled/streptavidin-precipitated protein frac
tion.
FIG. 6 shoWs reciprocal antibody titers in serum of EPM
con?rmed horses, determined by an ELISA using the recom

binant surface antigens of the present invention.
FIG. 7 shoWs reciprocal antibody titers in CSF of EPM
con?rmed horses, determined by an ELISA using the recom
binant surface antigens of the present invention.
FIG. 8 shoWs expression of S. neurona surface antigens in

BRIEF DESCRIPTION OF THE DRAWINGS

COS-1 (green monkey kidney) cells, detected by immunof
luorescent labeling With ?uorescein isothiocyanate.

FIG. 1 is a sequence comparison of mature SnSAG1 (SEQ

ID NO.:31), SnSAG4 (SEQ ID NO: 32), and SnSAG3 (SEQ
ID NO.: 33) With SmMSA (SEQ ID NO.: 34) and TgSAG2E
(SEQ ID NO.:35). The S. neurona surface antigens SnSAG1,

45

DETAILED DESCRIPTION OF THE INVENTION

SnSAG3 and SnSAG4 are most similar to the TgSAG2 family

The present invention may be understood more readily by
reference to the folloWing detailed description of speci?c

of T gondi surface antigens. The sequences presented in the
Figure are for the mature proteins after cleaving off the N-ter

50 the claims, “a” can mean one or more. As can be appreciated

embodiments and the examples included therein. As used in

minal signal peptide and the C-terminal signal for the GPI
anchor. Sequence alignments of the predicted mature proteins
revealed very moderate sequence identity (<25%). HoWever,

by one of skill in the art, methods and materials similar or
equivalent to those described herein can be used in the prac

the SnSAGs contain 10/12 conserved cysteine residues that
have been observed previously, suggesting that the SnSAGs

tions, patents, and other references mentioned herein are
incorporated by reference in their entirety in order to more
fully describe the state of the art to Which this invention
pertains. It is noted that the abbreviated citations of literature
referenced herein are set forth fully in US. patent application
Ser. No. 10/369,430, the disclosure ofWhich is also incorpo

tice of the present invention. All publications, patent applica
55

have a tertiary structure that is similar to What has been

determined for the TgSAGs/SRSs.
FIG. 2 is a sequence comparison of mature SnSAG2 (SEQ

ID NO.: 36) With TgSAG1 (SEQ ID NO.: 37) and TgSRS2
(SEQ ID NO.: 38). The sequences presented in the Figure are
for the mature proteins after cleaving off the N-terminal sig

60

nal peptide and the C-terminal signal for the GPI anchor. The

rated herein in its entirety by reference.
Although the present invention has been described With
reference to speci?c details of certain embodiments thereof, it

its TgSAG orthologues, but contains 6/6 conserved cysteine

is not intended that such details should be regarded as limi
tations upon the scope of the invention except as and to the
extent that they are included in the accompanying claims. In
the case of a con?ict With incorporated references, the present

residues that have been observed in each half of the proto

speci?cation, including de?nitions, Will control. In addition,

S. neurona surface antigen SnSAG2 is most similar to the

TgSAG1 family of T gondii surface antigens. Similar to the
other SnSAGs, SnSAG2 shares modest sequence identity to

65
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the particular embodiments discussed below are illustrative
only and not intended to be limiting.
The present invention satis?es the long felt need in the art

“polypeptide” and “protein” are used interchangeably and are
meant to include any peptide-linked chain of amino acids,

by providing novel isolated nucleic acid sequences Which
encode antigenic proteins derived from Sarcocyslis neurona,
or Which encode unique antigenic protein fragments thereof.

glycosylation or phosphorylation. By “puri?ed” polypeptide

As used herein, a “nucleic acid” means a chain of at least tWo
or more nucleotides such as DNA (deoxyribonucleic acid) or

or mixture in Which the polypeptide occurs.
Similar to other members of the Apicomplexa, S. neurona
is an obligate intracellular pathogen that utilizes a number of

regardless of length or post-translational modi?cation, e.g.,
is meant a polypeptide that has been substantially separated
or isolated aWay from other polypeptides in a cell, organism,

RNA (ribonucleic acid). As used herein, a “puri?ed” nucleic
acid is one that is substantially separated from other nucleic

unique structures and molecules (i.e., virulence factors) to
support its parasitic lifestyle. Parasite surface molecules are
virulence factors that are typically novel and undoubtedly
important since they are responsible for the initial interac

acid sequences in a cell or organism in Which the nucleic acid

naturally occurs. Likewise, by “isolated” nucleic acid is
meant separated from at least some of other nucleic acids

found in the naturally-occurring organism. The nucleic acids
of the present invention can include positive and negative

tions With the host cell surface and host immune response. In

Toxoplasma gondii, for example, an extensive family of 25+
surface antigens has been identi?ed, Which are developmen
tally regulated and exhibit various levels of sequence similar

strand RNA as Well as DNA. The above terms encompass

double-stranded DNA, single-stranded DNA, and RNA and
are meant to include genomic and subgenomic nucleic acids
found in the naturally-occurring Sarcocyslis neurona organ

ism. The nucleic acids contemplated by the present invention

ity to either of the major T gondii surface antigens TgSAGl
or TgSAG2. These surface molecules appear to be involved in
20

include a nucleic acid having sequences from Which a Sarco
cyslis neurona cDNA can be transcribed; or allelic variants

are involved in modulation of host immune responses.

and/or homologs of thereof. By “capable of selectively
hybridizing” is meant a sequence Which does not hybridize
With other nucleic acids to prevent an adequate positive
hybridization With nucleic acids from Sarcocyslis neurona
and is meant to include stringent hybridization conditions

In one embodiment, the present invention provides identity
25

that generated approximately 8500 expressed sequence tags

stringency conditions are knoWn in the art, e.g., in US Patent
30

meant a fragment of the nucleic acids set forth in the

contain an amino-terminal signal peptide and a carboxyl

derived from the novel sequences set forth herein or that can
35

neurona. Modi?cations to the nucleic acids of the invention
are also contemplated as long as the essential structure and

40

bases exist for selective hybridization (Kunkel et al. Methods
Enzmol. 1987: 154-367, 1987). As one of skill in the art can

appreciate, there can be naturally occurring allelic variants
and non-naturally occurring variants or modi?cations of the
nucleic acids of the invention. For example, homologs or
naturally occurring allelic variants of the nucleic acids of the

localization, and Triton X-l 14 partitioning and surface bioti

surface (See, FIGS. 4 and 5). Additionally, these novel S.
neurona proteins possess multiple conserved cysteine resi
dues that have been described previously for T gondii SAGs
and Which are likely important for the tertiary structure of the
proteins (See, FIGS. 1 and 2). Due to their surface localiza
tion and relative homology to T gondii surface antigens, these
S. neurona proteins have been designated SnSAGl, SnSAG2,
SnSAG3, and SnSAG4.
Accordingly, one embodiment of the present invention
comprises an isolated nucleic acid as set forth in the Sequence

invention having from about 50% and up to about 99%

sequence identity are contemplated by the invention. Like

Wise, it is contemplated that non-naturally occurring variants
or modi?cations of the nucleic acids of the invention can

terminal glycolipid anchor addition site, indicating surface
nylation assays con?rmed that all four proteins are mem
brane-associated and displayed on the S. neurona merozoite

function of the polypeptide encoded by the nucleic acids is
maintained. Likewise, fragments used as primers or probes
can have substitutions so long as enough complementary

(ESTs) from this organism. Examination of this sequence
database has revealed a family of at least four S. neurona

surface antigens that are orthologues of the SAG/SRS family
of surface proteins in T gondii. Each protein is predicted to

Sequence Listing that is less than the full length that can
selectively hybridize With a RNA, DNA or cDNA sequence

selectively hybridize With nucleic acids from Sarcocyslis

and characterization of certain of the virulence factors of S.
neurona. In particular, the present invention provides four
isolated nucleic acids of S. neurona (genes) that encode para

sitic surface antigens. A sequencing project Was conducted

including loW, moderate and high stringency conditions. Such
Publication No.: 2002/01 15828 A1. By “unique fragment” is

receptor/ligand interactions With the host cell surface, and
there is increasing evidence that some of the T gondii SAGs

50

listing as SEQ ID NO: 21. The nucleic acid identi?ed in SEQ
ID NO: 21 comprises an 828-nucleotide open reading frame

range from about 50% to about 99% sequence identity to

of the SnSAG1 gene of Sarcocyslis neurona Which encodes a

native S. neurona are contemplated.

276 amino acid polypeptide set forth in the Sequence Listing
as SEQ ID NO: 22. The polypeptide encoded by SEQ ID NO:

In particular, one embodiment of the present invention

provides isolated nucleic acids derived from three Sarcocyslis
neurona cluster sequences, namely Sn Cluster 144, Sn Clus
ter 21 and Sn Cluster 4, Which comprise the nucleotide
sequences set forth in the Sequence Listing as SEQ ID NOS:

1, 3, and 29 respectively and the sequences complimentary
thereto. Also provided by the invention are the corresponding
protein or polypeptide amino acid sequences for these three
Sarcocyslis neurona cluster sequences. The polypeptide

55

60

22 has a predicted amino-terminal signal peptide (indicating
expression via the secretory pathWay) and a glycolipid anchor
addition site at the carboxy-terminal end (indicating surface
localization). Database searches With the predicted protein
sequence of SnSAG1 (rSnSAGl) revealed signi?cant simi
larity (alignment score:80, E value:2><10—14) to a 31 kDa
surface antigen from Sarcocyslis muris.
A recombinant form of the Sarcocyslis neurona SnSAG1

sequence comprising Sn Cluster 144 is set forth in the

(rSnSAGl) has been expressed in E. coli. Western blot analy

Sequence Listing as SEQ ID NO: 2. The polypeptide

sis of rSnSAGl demonstrated that the recombinant antigen is
recognized by antiserum from a rabbit that Was immunized
With S. neurona merozoites and by antibodies in cerebrospi
nal ?uid (CSF) from an EPM (Sarcocyslis neurona infected)

sequence comprising Sn Cluster 21 is set forth in the

Sequence Listing as SEQ ID NO: 4 and the polypeptide
sequence comprising Sn Cluster 4 is set forth in the Sequence
Listing as SEQ ID NO: 30. As used herein, the terms

65

horse (See, e.g., FIG. 3).

US 7,524,946 B2
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Another embodiment of the present invention provides an

Another embodiment of the present invention comprises an
isolated nucleic acid as set forth in the Sequence listing as
SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID NO:
23 comprises an 975 nucleotide open reading frame of the

isolated nucleic acid designated SnGFlb Which comprises
the nucleic acid set forth in SEQ ID NO: 7 and sequences
complimentary thereto. Another embodiment of the invention

comprises the polypeptide sequence encoded by SnGFlb set
forth in the Sequence Listing as SEQ ID NO: 8.
Yet another embodiment of the present invention provides

SnSAG2 gene of Sarcocyslis neurona Which encodes a 168

amino acid polypeptide set forth in the Sequence Listing as
SEQ ID NO: 24.
The present invention also provides an isolated nucleic
acid as set forth in the Sequence listing as SEQ ID NO: 25.
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an
1585 nucleotide open reading frame of the SnSAG3 gene of

an isolated nucleic acid designated SnGFlc Which comprises
the nucleic acid set forth in SEQ ID NO: 9 and sequences
complimentary thereto. Another embodiment of the invention

comprises the polypeptide sequence encoded by SnGFlc set
forth in the Sequence Listing as SEQ ID NO: 10.
Still another embodiment of the present invention provides

Sarcocyslis neurona Which encodes a 281 amino acid

polypeptide set forth in the Sequence Listing as SEQ ID NO:

an isolated nucleic acid designated SnGF l d Which comprises
the nucleic acid set forth in SEQ ID NO: 11 and sequences
complimentary thereto. Another embodiment of the invention

26.

Also provided by the present invention is an isolated
nucleic acid as set forth in the Sequence listing as SEQ ID

comprises the polypeptide sequence encoded by SnGFld set
fort in the Sequence Listing as SEQ ID NO: 12.

NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27 com
prises an 1 l l l nucleotide open reading frame of the SnSAG4
gene of Sarcocyslis neurona Which encodes a 287 amino acid

polypeptide set forth in the Sequence Listing as SEQ ID NO:

20

28.
As set forth more fully beloW, these genes have been

expressed as recombinant proteins in E. coli. The recombi
nant SnSAG proteins can be implemented into antibody
capture ELISAs and used to detect the presence of S. neurona

25

antibodies in a sample. Likewise, the recombinant proteins
provided by the invention can be used as reagents for use in
vaccines against S. neurona.
Another embodiment of the present invention includes the

discovery of additional novel expressed sequence tags (EST)
that encode novel antigenic peptides for utiliZation in the
vaccines and diagnostic kits as disclosed by this invention.
In particular, cluster analysis of the Sarcocyslis neurona
expressed sequence tags (ESTs) generated from the cSn.l

35

comprises the polypeptide sequence encoded by SnGFlg set

40

forth in the Sequence Listing as SEQ ID NO: 18.
Still another embodiment of the present invention provides
an isolated nucleic acid designated SnGFlh Which comprises
the nucleic acid set forth in SEQ ID NO: 19 and sequences
complimentary thereto. Another embodiment of the invention

cDNA library has revealed a gene family that encodes at least

eight homologous proteins. Of the approximately 8500 S.
neurona ESTs that have been generated thus far, roughly 540
sequences can be placed in this gene family, Which has been

provisionally designated SnGFl (S. neurona Gene Family 1).
Based on its relative abundance in the collection of S. neurona

comprises the polypeptide sequence encoded by SnGFlh set
forth in the Sequence Listing as SEQ ID NO: 20.

ESTs, SnGFl encodes a set of similar proteins (at least eight)

that are highly expressed and most likely play signi?cant
roles in the biology of S. neurona (i.e., parasite virulence
factors). In addition to their biological importance, the abun

dance of these proteins Would suggest that they elicit signi?

The present invention provides isolated nucleic acids as set

forth in the Sequence Listing and nucleic acid reagents
45

cant immune responses in infected animals. Collectively, the
characteristics of the novel nucleic acids of SnGFl, and the

encoded proteins therefrom, make this gene family Well
suited for the development of improved diagnostics and/or

The present invention also provides an isolated nucleic
acid designated SnGFle Which comprises the nucleic acid set
fort in SEQ ID NO: 13 and sequences complimentary thereto.
Another embodiment of the invention comprises the polypep
tide sequence encoded by SnGFle set forth in the Sequence
Listing as SEQ ID NO: 14.
Another embodiment of the present invention provides an
isolated nucleic acid designated SnGF l f Which comprises the
nucleic acid set forth in SEQ ID NO: 15 and sequences
complimentary thereto. Another embodiment of the invention
comprises the polypeptide sequence encoded by SnGFlf set
forth in the Sequence Listing as SEQ ID NO: 16.
Yet another embodiment of the present invention provides
an isolated nucleic acid designated SnGF l g Which comprises
the nucleic acid set forth in SEQ ID NO: 17 and sequences
complimentary thereto. Another embodiment of the invention

50

derived therefrom Which can be utiliZed to diagnose and
prevent infection of S. neurona. Puri?ed polypeptides
encoded by the nucleic acids are also provided. These
polypeptides can be utiliZed in methods of diagnosis or as
vaccine components for prevention of infection. Vectors are

also provided Which comprise the nucleic acids of the present

vaccines for EPM as set forth herein.

invention. The vectors can be utiliZed in host expression

The eight SnGFl isoforms identi?ed thus far have been
designated SnGFla-h. These genes are predicted to encode

and prophylactic applications. The present invention also pro

proteins of, e.g., 109 amino acids, 106 amino acids, and 107
amino acids in length, and the proteins share approximately

systems to produce antigenic peptide reagents for diagnostic
55

vides puri?ed antibodies selectively reactive With S. neurona.
These antibodies can be used in various diagnostic methods

70% to 80% sequence identity. These proteins have a pre

or as a therapeutic.

dicted N-terminal signal peptide and a predicted transmem

In one embodiment, the invention provides puri?ed anti
genic polypeptides encoded by the nucleic acids set forth in
the Sequence Listing. The invention also provides these anti
genic polypeptides in a pharmaceutically acceptable carrier.

brane domain near the C-terminus. The SnGFl members
shoW no similarity to sequences in the current public gene

databases, suggesting that SnGFl is relatively unique to S.

60

The amino acid sequence of these polypeptides can be
deduced from the nucleotide sequences set forth in the

neurona.

Accordingly, one embodiment of the present invention
provides an isolated nucleic acid designated SnGFla Which
comprises the nucleic acid set fort in SEQ ID NO: 5 and
sequences complimentary thereto. Another embodiment of

the invention comprises the polypeptide sequence encoded by
SnGFla set forth in the Sequence Listing as SEQ ID NO: 6.

Sequence Listing.
Puri?ed antigenic polypeptide fragments encoded by the
65

nucleic acids of the present invention are also contemplated.
As used herein, “puri?ed” means the antigen is at least su?i
ciently free of contaminants or cell components With Which

US 7,524,946 B2
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the antigen normally occurs to distinguish the antigen from
the contaminants or components. Puri?ed antigenic polypep

skill in the art useful for the expression of the antigen. Other
microbial hosts suitable for use include bacilli, such as Bacil

tides of S. neurona and antigenic fragments thereof of the

lus sublil is, and other enterobacteriaceae, such as Salmonella,

present invention are also referred to herein as “the antigen”
or “the S. neurona antigen.” It is contemplated that the anti

Serralia, and various Pseudomonas species. In these prokary

genic fragments can be encoded from any portion of the

typically contain expression control sequences compatible

nucleic acid encoding S. neurona as set forth in the Sequence

With the host cell (e.g., an origin of replication). In addition,

Listing, but especially from fragments encoded by the open

any number of a variety of Well-known promoters can be
present, such as the lactose promoter system, a tryptophan
(Trp) promoter system, a beta-lactamase promoter system, or
a promoter system from phage lambda. The promoters Will

otic hosts one can also make expression vectors, Which Will

reading frames set forth in SEQ ID NOS: 24, 26 and 28 as
described herein. Speci?cally, one example provides an

approximately 12 kDa antigenic polypeptide encoded by an
open reading frame of SEQ ID NO: 24 consisting essentially

typically control expression, optionally With an operator

of the amino acids encoded by the nucleotide as sequence set

sequence, and have ribosome binding site sequences for

forth in the Sequence Listing as SEQ ID NO: 23.
An antigenic fragment of the antigen can be isolated from
the Whole antigen by chemical or mechanical disruption. The
puri?ed fragments thus obtained can be tested to determine

example, for initiating and completing transcription and
translation. If necessary, for example, an amino terminal
methionine can be provided by insertion of a Met codon 5' and

in-frame With the antigen. Also, the carboxyterminal exten
sion of the antigenic fragments can be removed using stan

their antigenicity and speci?city by the methods taught

dard oligonucleotide mutagenesis procedures.

herein. Antigenic fragments of the antigen can also be syn

thesiZed directly. An immunoreactive fragment is generally

20

Additionally, yeast expression can be used. There are sev

an amino acid sequence of at least about ?ve consecutive

eral advantages to yeast expression systems. First, evidence

amino acids derived from the antigen amino acid sequence.
The polypeptide fragments of the present invention can

exists that proteins produced in a yeast secretion systems
exhibit correct disul?de pairing. Second, post-translational
glycosylation is e?iciently carried out by yeast secretory sys

also be recombinant proteins obtained by cloning nucleic
acids encoding the polypeptide in an expression system
capable of producing the antigenic polypeptide or fragments

25

alpha-factor leader region (encoded by the MF.alpha.-l gene)
is routinely used to direct protein secretion from yeast (Brake
et al., 1984). The leader region of pre-pro-alpha-factor con

thereof.
Once the amino acid sequence of the antigen is provided, it

is also possible to synthesiZe, using standard peptide synthe
sis techniques, peptide fragments chosen to be homologous to
immunoreactive regions of the antigen and to modify these
fragments by inclusion, deletion or modi?cation of particular
amino acids residues in the derived sequences. Thus, synthe
sis or puri?cation of an extremely large number of peptides
derived from the antigen is possible.

tems. In one example, the Saccharomyces cerevisiae pre-pro

tains a signal peptide and a pro-segment Which includes a
30

recognition sequence for a yeast protease encoded by the
KEX2 gene: this enZyme cleaves the precursor protein on the

carboxyl side of a Lys-Arg dipeptide cleavage-signal
35

The amino acid sequences of the present polypeptides can
contain an immunoreactive portion of the S. neurona antigen
attached to sequences designed to provide for some addi
tional property, such as solubility. The amino acid sequences

sequence. The antigen coding sequence can be fused in-frame
to the pre-pro-alpha-factor leader region. This construct is
then put under the control of a strong transcription promoter,
such as the alcohol dehydrogenase I promoter or a glycolytic

promoter. The antigen coding sequence is folloWed by a trans
lation termination codon Which is folloWed by transcription

termination signals. Alternatively, the antigen coding

of an S. neurona antigen can include sequences in Which one 40 sequences can be fused to a second protein coding sequence,
or more amino acids have been substituted With another
such as Sj26 or .beta.-galactosidase, used to facilitate puri?

amino acid to provide for some additional property, such as to

cation of the fusion protein by a?inity chromatography. The

remove/ add amino acids capable of disul?de bonding, to
increase its bio-longevity, alter enzymatic activity, or alter
interactions, e.g., With gastric acidity. In any case, the peptide

insertion of protease cleavage sites to separate the compo
nents of the fusion protein is applicable to constructs used for
45

immunogenicity, etc.
The puri?ed polypeptide fragments thus obtained can be
tested to determine their immunogenicity and speci?city.
Brie?y, various concentrations of a putative immunogeni
cally speci?c fragment are prepared and administered to an
animal and the immunological response (e.g., the production

cations such as folding and cysteine pairing, addition of com

plex carbohydrate structures, and secretion of active protein.
50

Vectors useful for the expression of antigen in mammalian
cells are characterized by insertion of the antigen coding
sequence betWeen a strong viral promoter and a polyadeny
lation signal. The vectors can contain genes conferring either

of antibodies or cell mediated immunity) of an animal to each

concentration is determined. The amounts of antigen admin
istered depend on the subject, e. g. a horse or a guinea pig, the

expression in yeast.
Mammalian cells permit the expression of proteins in an
environment that favors important post-translational modi?

should posses a bioactive property, such as immunoreactivity,

gentamicin or methotrexate resistance for use as selectable
55

markers. The antigen and immunoreactive fragment coding

condition of the subject, the siZe of the subject, etc. Thereafter

sequence can be introduced into a Chinese hamster ovary cell

an animal so inoculated With the antigen can be exposed to the

line using a methotrexate resistance-encoding vector. Pres

parasite to test the potential vaccine effect of the speci?c
immunogenic fragment. The speci?city of a putative immu
nogenic fragment can be ascertained by testing sera, other

ence of the vector DNA in transformed cells can be con?rmed
60

?uids or lymphocytes from the inoculated animal for cross

reactivity With other closely related Sarcocyslis spp.

suitable host cell lines capable of secreting intact proteins
have been developed in the art, and include the CHO cell

A vector comprising the nucleic acids of the present inven

lines, HeLa cells, myeloma cell lines, Jurkat cells, etc.

tion is also provided. The vectors of the invention can be in a

host capable of expressing the antigenic polypeptide frag

by Southern analysis and production of a cDNA or opposite
strand RNA corresponding to the antigen coding sequence
can be con?rmed by northern analysis. A number of other

65

Expression vectors for these cells can include expression

ments contemplated by the present invention. There are

control sequences, such as an origin of replication, a pro

numerous E. coli expression vectors knoWn to one of ordinary

moter, an enhancer, and necessary information processing
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sites, such as ribosome binding sites, RNA splice sites, poly
adenylation sites, and transcriptional terminator sequences.

moieties contemplated by the present invention include, but
are not limited to ?uorescent, enzymatic and radioactive
markers.

Preferred expression control sequences are promoters derived

from immunoglobulin genes, SV40, Adenovirus, Bovine
Papilloma Virus, etc. The vectors containing the nucleic acid

A puri?ed S. neurona antigen bound to a substrate and a

ligand speci?cally reactive With the antigen are also contem
plated. Such a puri?ed ligand speci?cally reactive With the

segments of interest can be transferred into the host cell by
Well-knoWn methods, Which vary depending on the type of
cellular host. For example, calcium chloride transfection is

antigen can be an antibody. The antibody can be a monoclonal

antibody obtained by standard methods and as described
herein. The monoclonal antibody can be secreted by a hybri

commonly utilized for prokaryotic cells, Whereas calcium

doma cell line speci?cally produced for that purpose (HarloW
and Lane, 1988). Likewise, nonhuman polyclonal antibodies

phosphate treatment or electroporation may be used for other
cellular hosts.
Alternative vectors for the expression of antigen in mam
malian cells can be employed, similar to those developed for

speci?cally reactive With the antigen are Within the scope of
the present invention. The polyclonal antibody can also be
obtained by the standard immunization and puri?cation pro

the expression of human gammainterferon, tissue plasmino
gen activator, clotting Factor VIII, hepatitis B virus surface

tocols (HarloW and Lane, 1988).

antigen, protease Nexinl, and eosinophil major basic protein.

The present invention provides a method of detecting the

Further, the vector can include CMV promoter sequences and

presence of S. neurona in a subject, comprising the steps of

a polyadenylation signal available for expression of inserted
nucleic acid in mammalian cells (such as COS7).
The nucleic acid sequences can be expressed in hosts after
the sequences have been operably linked to, i.e., positioned to
ensure the functioning of, an expression control sequence.
These expression vectors are typically replicable in the host
organisms either as episomes or as an integral part of the host
chromosomal DNA. Commonly, expression vectors can con

contacting an antibody-containing sample from the subject
20

ence of the S. neurona or a previous infection With S. neurona.

25

tain selection markers, e.g., tetracycline resistance or hygro
mycin resistance, to permit detection and/or selection of those
cells transformed With the desired nucleic acid sequences

(see, e.g., US. Pat. No. 4,704,362).
Polynucleotides encoding a variant polypeptide may
include sequences that facilitate transcription (expression
sequences) and translation of the coding sequences such that

30

sample of this method can comprise any body ?uid Which
Would contain the antigen or a cell containing the antigen,
35

termination site (polyadenylation site in eukaryotic expres
sion hosts), a ribosome binding site, and, optionally, an
enhancer for use in eukaryotic expression hosts, and, option
ally, sequences necessary for replication of a vector.
40

vector constructs, for example, as set forth in US. Pat. Nos.

5,643,576; 5,843,723; 6,156,558; and 6,242,259, the teach
ings of Which are hereby incorporated herein by reference.
A puri?ed monoclonal antibody speci?cally reactive With

Will be fragments of the antigen. As contemplated herein, the
antibody includes any ligand Which binds the antigen, for
example, an intact antibody, a fragment of an antibody or

of such polynucleotides is Well knoWn in the art. For example,

One presently preferred vector system for expression of the
peptides of the invention comprises the use of Alphavirus

One example of the method of detecting S. neurona is
performed by contacting a ?uid or tissue sample from the
subject With an amount of a puri?ed antibody speci?cally
reactive With the antigen as de?ned herein, and detecting the
reaction of the ligand With the antigen. It is contemplated that
the antigen Will be on intact cells containing the antigen, or

another reagent that has reactivity With the antigen. The ?uid

the encoded polypeptide product is produced. Construction
such polynucleotides can include a promoter, a transcription

With a detectable amount of the antigenic polypeptide frag
ment of the present invention and detecting the reaction of the
fragment and the antibody, the reaction indicating the pres

such as blood, plasma, serum, cerebrospinal ?uid, saliva,
feces and urine. Other possible examples of body ?uids
include sputum, mucus, gastric juice and the like.
Enzyme immunoassays such as immuno?uorescence
assays (IFA), enzyme linked immunosorbent assays (ELISA)
and immunoblotting can be readily adapted to accomplish the
detection of the antigen. An ELISA method effective for the
detection of the antigen can, for example, be as folloWs: (1)
bind the antibody to a substrate; (2) contact the bound anti

body With a ?uid or tissue sample containing the antigen; (3)
45

contact the above With a secondary antibody bound to a

detectable moiety (e.g., horseradish peroxidase enzyme or
alkaline phosphatase enzyme); (4) contact the above With the

S. neurona is also provided. The antibodies can be speci?cally
reactive With a unique epitope of the antigen or they can also

react With epitopes of other organisms. The term “reactive”

substrate for the enzyme; (5) contact the above With a color

means capable of binding or otherWise associating non ran
refers to an antibody or other ligand that does not cross react

reagent; (6) observe color change. The above method can be
readily modi?ed to detect antibody as Well as antigen.
Another immunologic technique that can be useful in the

substantially With any antigen other than the one speci?ed, in

detection of S. neurona or previous S. neurona infection uti

this case, S. neurona. Antibodies can be made as described in

lizes monoclonal antibodies (MAbs) for detection of antibod
ies speci?cally reactive With S. neurona antigen. Brie?y, sera
or other body ?uids from the subject is reacted With the
antigen bound to a substrate (eg an ELISA 96-Well plate).
Excess sera is thoroughly Washed aWay. A labeled (enzyme

domly With an antigen. “Speci?cally reactive” as used herein

the Examples (see also, HarloW and Lane, Antibodies; A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y., 1988). Brie?y puri?ed antigen can be

50
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injected into an animal in an amount and in intervals suf?cient
to elicit an immune response. Antibodies can either be puri

led, ?uorescent, radioactive, etc.) monoclonal antibody is

?ed directly, or spleen cells can be obtained from the animal.
The cells are then fused With an immortal cell line and
screened for antibody secretion. The antibodies can be used to

60

screen clone libraries for cells secreting the antigen. Those

positive clones can then be sequenced (see, for example,
Kelly et al., Bio/Technology, 10: 163-167, (1992) and Beb

bington et al., Bio/Technology, 10: 169-175, (1992).
The antibody can be bound to a substrate or labeled With a

detectable moiety or both bound and labeled. The detectable

then reacted With the previously reacted antigen serum anti
body complex. The amount of inhibition of monoclonal anti
body binding is measured relative to a control (no patient
serum antibody). The degree of monoclonal antibody inhibi
tion is a very speci?c test for a particular variety or strain since

65

it is based on monoclonal antibody binding speci?city. MAbs
can also be used for detection directly in cells by IFA.
A micro-agglutination test can also be used to detect the
presence of S. neurona in a subject. Brie?y, latex beads (or red
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blood cells) are coated With the antigen and mixed With a
sample from the subj ect, such that antibodies in the tissue or

Which case it can be selected by standard criteria based on the

antigen used, the mode of administration and the subject
(Arnon, R. (Ed.). 1987). Methods of administration can be by

body ?uids that are speci?cally reactive With the antigen

crosslink With the antigen, causing agglutination. The agglu

oral or sublingual means, or by injection, depending on the
particular vaccine used and the subject to Whom it is admin
istered.

tinated antigen-antibody complexes form a precipitate, vis
ible With the naked eye or capable of being detected by a
spectrophotometer. In a modi?cation of the above test, anti
bodies speci?cally reactive With the antigen can be bound to
the beads and antigen in the tissue or body ?uid thereby
detected.
In addition, as in a typical sandWich assay, the antibody can
be bound to a substrate and reacted With the antigen. There
after, a secondary labeled antibody is bound to epitopes not

It can be appreciated from the above that the vaccine can be
used as a prophylactic or a therapeutic modality. Thus, the
invention provides methods of preventing or treating S. neu

rona infection and the associated diseases by administering
the vaccine to a subject.
Nucleic acid vaccines against S. neurona are also contem

plated by the invention. The antigenic agent for use in the

recogniZed by the ?rst antibody and the secondary antibody is

vaccines of the invention can be any nucleic acid, e.g., as set
forth in the Sequence Listing, that can stimulate an immune

detected. Since the present invention provides S. neurona
antigen for the detection of infectious, S. neurona or previous

response against, e.g., SnSAG2, SnSAG3 or SnSAG4 When
administered to a subject. Suitable nucleic acids include those
that encode the native proteins of S. neurona, e.g., SnSAG2,

S. neurona infection other serological methods such as ?oW
cytometry and immunoprecipitation can also be used as

detection methods.

In the diagnostic methods taught herein, the antigen can be

SnSAG3 or SnSAG4 protein or a variant or antigenic peptide
20

bound to a substrate and contacted by a ?uid sample such as

fragment thereof, such as, e.g., the nucleic acid set forth in the
Sequence listing as SEQ ID NO:23, SEQ ID NO:25 or SEQ

serum, cerebrospinal ?uid, urine, saliva, feces or gastric juice.

ID NO:27. The nucleic acid used as a vaccine can be e.g., a

This sample can be taken directly from the patient or in a

naked DNA, or the nucleic acid can be incorporated in an
expression vector as set forth herein, e.g., in an Alpha virus

partially puri?ed form. In this manner, antibodies speci?c for

the antigen (the primary antibody) Will speci?cally react With

25

the bound antigen. Thereafter, a secondary antibody bound to,
or labeled With, a detectable moiety can be added to enhance

the detection of the primary antibody. Generally, the second
ary antibody or other ligand Which is reactive, either speci?
cally With a different epitope of the antigen or nonspeci?cally

30

With, the ligand or reacted antibody, Will be selected for its
ability to react With multiple sites on the primary antibody.
Thus, for example, several molecules of the secondary anti

The presence of S. neurona can also be determined by
detecting the presence of a nucleic acid speci?c for S. neurona
or the antigens of S. neurona encoded by the nucleic acids set
forth herein. The present invention provides a method of
detecting the presence of S. neurona in a subject, comprising
detecting the presence of the nucleic acid encoding an S.

neurona antigen. As set forth more fully in the examples
beloW, the speci?city of these sequences for S. neurona can be

determined by conducting a computerized comparison With

body can react With each primary antibody, making the pri
mary antibody more detectable.
The detectable moiety Will alloW visual detection of a

vector (see, e.g., Rosenberg, S. A., Immunity 101281, 1999).

35

knoWn sequences, catalogued in GenBank, a computeriZed
database, using the computer programs Word Search or

precipitate or a color change, visual detection by microscopy,

FASTA of the Genetics Computer Group (Madison, Wis.),

or automated detection by spectrometry, radiometric mea
surement or the like. Examples of detectable moieties include

Which search the catalogued nucleotide sequences for simi
larities to the nucleic acid in question.
The nucleic acid speci?c for S. neurona antigen can be
detected utiliZing a nucleic acid ampli?cation technique, such
as polymerase chain reaction or ligase chain reaction. Alter

?uorescein and rhodamine (for ?uorescence microscopy),
horseradish peroxidase (for either light or electron micros

40

copy and biochemical detection), biotin-streptavidin (for
light or electron microscopy) and alkaline phosphatase (for
biochemical detection by color change). The detection meth
ods and moieties used can be selected, for example, from the
list above or other suitable examples by the standard criteria

45

natively, the nucleic acid is detected utiliZing direct hybrid
iZation or by utiliZing a restriction fragment length polymor
phism. For example, the present invention provides a method
of detecting the presence of S. neurona comprising ascertain

applied to such selections (HarloW and Lane, 1988).
The antigen, e.g., a puri?ed antigenic polypeptide frag

restriction endonuclease cleavage site. In addition, PCR

ment encoded by the Sequence Listing of this invention can

primers Which hybridiZe only With nucleic acids speci?c for

be used in the construction of a vaccine comprising an immu

ing the presence of a nucleotide sequence associated With a

50

nogenic mount of the antigen and a pharmaceutically accept
able carrier. The vaccine can be the entire antigen, the antigen

can be sequenced directly using, techniques knoWn in the art
and described herein and compared to the knoWn unique

on an intact S. neurona organism, E. coli or other strain, or an

epitope speci?c to the antigen. The vaccine can also be poten
tially cross-reactive With antibodies to other antigens. The

S. neurona can be utiliZed. The presence of ampli?cation
indicates the presence of S. neurona sequence. In another
embodiment a restriction fragment of a nucleic acid sample

55

sequence to detect S. neurona. In a further embodiment, the

present invention provides a method of detecting the presence
of S. neurona by selective ampli?cation by the methods

vaccine can then be used in a method of preventing EPM or
other complications of S. neurona infection.

Immunogenic amounts of the antigen can be determined

described herein. In yet another embodiment S. neurona can

using standard procedures. Brie?y, various concentrations of
a putative speci?c immunoreactive epitope are prepared,

be detected by directly hybridiZing the unique sequence With
60

(e. g., the production of antibodies) of an animal to each
concentration is determined.

The pharmaceutically acceptable carrier can comprise
saline or other suitable carriers (Arnon, R. (Ed.) Synthetic
Vaccines I: 83-92, CRC Press, Inc., Boca Raton, Fla., 1987).
An adjuvant can also be a part of the carrier of the vaccine, in

a S. neurona selective nucleic acid probe. Furthermore, the

nucleotide sequence could be ampli?ed prior to hybridization
by the methods described above.

administered to an animal and the immunological response

65

Altemative probing techniques, such as ligase chain reac
tion (LCR), involve the use of mismatch probes, i.e., probes
Which are fully complementary With the target except at the
point of the mutation. The target sequence is then alloWed to

hybridiZe both With oligonucleotides Which are fully comple
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mentary and have oligonucleotides containing a mismatch,
under conditions Which Will distinguish between the tWo. By
manipulating the reaction conditions, it is possible to obtain
hybridization only Where there is fall complementarity. If a
mismatch is present there is signi?cantly reduced hybridiza

times are: 20 mins denaturing; 35 cycles of 2 min, 1 min, 1
min for annealing, extension and denaturation; and ?nally a 5
min extension step.

PCR ampli?cation of speci?c alleles (PASA) is a rapid
method of detecting single-base mutations or polymor
phisms. PASA (also knoWn as allele speci?c ampli?cation)
involves ampli?cation With tWo oligonucleotide primers such
that one is allele-speci?c. The desired allele is ef?ciently

tion.
The polymerase chain reaction (PCR) and reverse tran

scriptase PCR are techniques that amplify speci?c nucleic
acid sequences With remarkable e?iciency. Repeated cycles
of denaturation, primer annealing and extension carried out

ampli?ed, While the other allele(s) is poorly ampli?ed
because it mismatches With a base at or near the 3' end of the

allele-speci?c primer. Thus, PASA or the related method of
PAMSA may be used to speci?cally amplify the mutation
sequences of the invention. Where such ampli?cation is done

With polymerase; e.g., a heat stable enZyme Taq polymerase,
leads to exponential increases in the concentration of desired
nucleic acid sequences. Given a knowledge of the nucleotide
sequence of S. neurona as set forth herein, synthetic oligo
nucleotides can be prepared Which are complementary to
sequences Which ?ank the nucleic acid of interest. Each oli
gonucleotide is complementary to one of the tWo strands. The
nucleic acid can be denatured at high temperatures (e.g.,

95.degree. C.) and then reannealed in the presence of a large
molar excess of oligonucleotides. The oligonucleotides, ori
ented With their 3' ends pointing toWards each other, hybridiZe
to opposite strands of the target sequence and prime enZy
matic extension along the nucleic acid template. The end

on S. neurona isolates or samples obtained from an indi
vidual, it can serve as a method of detecting the presence of S.
neurona. As mentioned above, a method knoWn as ligase

chain reaction (LCR) can be used to successfully detect a
single-base substitution. LCR probes may be combined or

multiplexed for simultaneously screening for multiple differ
20

product is then denatured again for another cycle. After this

three-step cycle has been repeated several times, ampli?ca

25

ent mutations. Thus, LCR can be particularly useful Where, as
here, multiple mutations are predictive of the same disease.
The present invention is more particularly described in the
folloWing examples Which are intended as illustrative only,
since numerous modi?cations and variations therein Will be
apparent to those skilled in the art.

tion of a nucleic acid segment by more than one million-fold
can be achieved. The resulting nucleic acid may then be

EXAMPLES

directly sequenced.
In yet another method, PCR may be folloWed by restriction

endonuclease digestion With subsequent analysis of the

30

resultant products. Nucleotide substitutions can result in the
gain or loss of speci?c restriction endonuclease sites. The
gain or loss of a restriction endonuclease recognition site

facilitates the detection of the organism using restriction frag
ment length polymorphism (RFLP) analysis or by detection

Identi?cation and CharacteriZation of SnSAGl

Surface biotinylation of extracellular meroZoites revealed
only tWo dominant labeled molecules that migrate at about 30
kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona EST

database (currently 1800+ sequences) identi?ed an ortho
35

logue of the 31-kDa surface antigen from Sarcocyslis muris.

dental plaque, other bodily ?uids of the subject suspected of

The sequence of the S. neurona surface antigen gene, desig
nated SnSAGl, is predicted to encode a 276-residue protein
With an amino-terminal signal peptide and a carboxy-termi
nal GPI anchor addition. Antiserum raised against recombi
nant SnSAGl recogniZed a 25-kDa antigen in Western blots
of non-reduced S. neurona lysates, consistent With the
molecular Weight predicted for the mature SnSAGl. Under

containing S. neurona, is digested With a restriction endonu

reducing conditions, SnSAGl migrated aberrantly at about

clease, and subsequently separated on the basis of siZe by
agarose gel electrophoresis. The Southern blot technique can
then be used to detect, by hybridization With labeled probes,
the products of endonuclease digestion. The patterns obtained

analyses of reduced T gondii surface antigens. lmmuno?uo
rescence labeling of SnSAGl during intracellular groWth of
S. neurona indicated that the protein is expressed throughout

from the Southern blot can then be compared. Using such an
approach, S. neurona nucleic acid is detected and their mobil

schiZogony. Interestingly, a ?lamentous staining pattern Was
observed in intermediate schiZonts that likely re?ects local

of the presence or absence of a polymorphic restriction endo
nuclease site in a PCR product that spans the sequence of
interest.

For RFLP analysis, nucleic acid is obtained, for example

from the blood, cerebrospinal ?uid, gastric specimen, saliva,

ity on the gel by determining the number of bands detected
and comparing this pattern to the nucleic acid from S. neu

40

30 kDa, similar to What has been observed in Western blot

50

rona.

Parasite Culture
S. neurona strain SN3 [Granstrom, 1992 #1600] meroZoi
tes Were propagated by serial passage in bovine turbinate

Similar creation of additional restriction sites by nucle
otide substitutions at the disclosed mutation sites can be

readily calculated by reference to the genetic code and a list of

55

nucleotide sequences recogniZed by restriction endonu
cleases. Single strand conformational analysis (SSCA) offers
a relatively quick method of detecting sequence changes

Pen/ Strep FungiZone (BioWittaker, lnc .). Extracellular mero
Zoites Were harvested and puri?ed from disrupted host cell
60

monolayers by ?ltration through 3.0 pm membranes, as
described previously for Neospora caninium [HoWe, 1997

#1372].

ampli?cation is obtained When both primers are the same

length and With roughly the same nucleotide composition.
Denaturation of strands usually takes place at about
94.degree. C. and extension from the primers is usually at
about 72.degree. C. The annealing temperature varies accord
ing to the sequence under investigation. Examples of reaction

(BT) cells and maintained in RPMI 1640 medium supple
mented With 10% fetal bovine serum, 2 mM sodium pyruvate,

Which may be appropriate in at least some instances.

In general, primers for PCR and LCR are usually about 20
bp in length and the preferable range is from 15-25 bp. Better

iZation of the surface antigen to previously-described invagi
nations of the schiZont surface membrane.

lmmunoscreen of S. neurona cDNA Library
Construction and analyses of the cSn.1 S. neurona mero
65

Zoite cDNA library has been described previously [HoWe,
2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on
XLl -Blue MRF' E. coli host cells (Stratagene) groWn on 150
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mm NZY agar plates. When plaques became visible, plates
Were overlayed With nitrocellulose ?lters previously soaked
in 10 mM isopropyl-[3-D-thiogalactopyranoside (IPTG) for

digested With NdeI and XhoI, ligated into NdeI/XhoI-di
gested pET22b expression vector (Novagen), and trans
formed into INVotF' E. coli. The resulting expression plas
mid, designated prSnSAG1, Was transformed into BL21

an additional 3 hr incubation at 370 C. Filters Were lifted from

the plates, Washed With TNT buffer (10 mM Tris-HCl, pH 7 .5,
150 mM NaCl, 0.05% TWeen 20), and blocked in phosphate
buffered saline (PBS), 5% dry milk, 5% normal goat serum,

CodonPlus E. coli (Stratagene), and a clone that expressed
high levels of recombinant SnSAG1 (rSnSAGl) Was selected
for use. The histidine-tagged rSnSAG1 Was puri?ed by
nickel-column chromatography according to the manufactur

0.05% TWeen 20.

Antigenic cDNA clones Were identi?ed by screening With
cerebrospinal ?uid (CSF) from a horse that had been naturally

er’s protocol (N ovagen), and monospeci?c polyclonal antis
era Were produced against the puri?ed protein by immuniza
tion of a rabbit and rat (Cocalico Biologicals, Inc.).

infected With S. neurona and exhibited a high titer of intrath
ecal antibodies against S. neurona in Western blot analysis.
Prior to screening the S. neurona cDNA library, the CSF Was

Western Blot Analysis
Parasites Were lysed in sodium dodecyl sulfate (SDS)
sample buffer supplemented With protease inhibitor cocktail
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were
separated in 10% or 12% polyacrylamide gels [Laemmli,

diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal goat serum,
0.05% TWeen 20 and incubated for 30 min With ?lters carry

ing plaque lifts of a previously-described N. caninum cDNA
library [HoWe, 1999 #1759] to remove antibodies that Were

reactive With E. coli and phage proteins. After adsorption of
potential cross-reactive antibodies, the diluted CSF solution
Was incubated for 1 hr With the cSn.1 ?lters. After Washing,
?lters Were incubated for 1 hr With goat anti-equine IgG

1970 #393]. Proteins Were transferred to nitrocellulose mem
20

buffer (pH 8.3). Membranes Were blocked With PBS contain

ing 5% nonfat dry milk, 5% goat serum, and 0.05% TWeen 20,
and then incubated for 1 hr With primary antibody. After
Washing, membranes Were incubated With HRP-conjugated

conjugated to horseradish peroxidase (HRP) (Jackson Immu
noresearch Labs, Inc.) diluted to 110,000. Immuno-reactive
phage plaques Were picked With sterile pipet tips and sus
pended in 40 pl of SM buffer (50 mM Tris-HCl, pH 7.5, 100
mM NaCl, 8 mM MgSO4, 0.01% gelatin). The cDNA inserts
Were PCR ampli?ed using the T3 and T7 oligonucleotide
primers, and the resulting products Were analyZed by agarose

25

search Labs, Inc.). Blots Were Washed, processed for chemi

Company), and exposed to ?lm.
30

nary identi?cation of the immunoreactive clones. Phagemid
excision Was performed on selected cDNA clones, and plas
mids Were rescued in SOLR cells according to the manufac

turer’s protocol (Stratagene).
S. neurona EST Database Searches and Sequence Analyses

7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2%
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With

search tool) set of programs [Altschul, 1990 #616]. At the
time the database Was searched, it contained 686 consensus
sequences that had been generated from 1883 S. neurona
ESTs. Selected cDNAs Were obtained from the archived col

RNase, DNase, protease inhibitor cocktail, and the sample
Was centrifuged at 16,000><g to remove the insoluble fraction.
The soluble proteins Were incubated With UltraLink immo
45

Elmer Applied Biosystems). The reactions Were puri?ed

50

trails deposited by gliding parasites, freshly lysed meroZoites

Center for Biotechnology Information (NCBI) Web site (See,
e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Protein Analy
sis System (ExPASy) server of the SWiss Institute of Bioin
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Were suspended in fresh RPMI 1640 and incubated on poly
L-lysine-coated slides for approximately 30 min. Slides Were
Washed With PBS, and the parasites Were ?xed in 2.5% for

malin-PBS containing 0.01% glutaraldehyde. For detection
of SnSAG1 on intracellularparasites, meroZoites Were inocu
lated onto BT cells groWn on LabTek chamber slides (Nuc).
At 24 hr, 48 hr, or 72 hr post-inoculation, the cells Were ?xed

ited into GenBank under accession number AY032845.

Recombinant SnSAG1 Expression and Generation of Poly

Immuno?uorescent Labeling of Extracellular and Intracellu
lar Parasites
For detection of SnSAG1 on extracellular parasites and in

vereux, 1984 #1 176] and programs available on the National

formatics (See, e.g., WWW.expasy.ch/). Multiple sequence
alignments Were performed using Multalin softWare [Corpet,
1988 #2046]. The sequence reported herein has been depos

biliZed streptavidin (Pierce), and the precipitated biotin-la
beled protein fraction Was analyZed by Western blotting, as
described above.

using Centri-Sep spin columns (Princeton Separations), and
ducted With Genetics Computer Group (GCG) softWare [De

0.5 mg/ml and incubated at room temperature for 30 min. The
labeled parasites Were Washed tWice With 5 ml of PBS and
stored at —200 C.

immunoprecipitation assay (RIPA) buffer (50 mM Tris [pH

sarco/index.html) using the BLAST (basic local alignment

the eluted extension products Were resolved and analyZed on
an ABI 310 Genetic AnalyZer. Sequence analyses Were con

Immobilized Streptavidin
Approximately 3><107 freshly harvested meroZoites Were
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy

The labeled parasite pellet Was lysed With 1 ml radio

clustered EST database (See, e.g., paradb.cis.upenn.edu/

Dye Terminator Cycle Sequencing reaction mix (Perkin

Biotinylation of Surface Proteins and Precipitation With

succinimide-biotin (Pierce) Was added to a concentration of
35

S. neurona homologues to previously-characterized coc
cidian surface antigens Were identi?ed in the S. neurona

lection of EST clones and sequenced using ABI Prism Big

immunoglobulin G secondary antibody (Jackson Immunore
luminescence using Supersignal substrate (Pierce Chemical

gel electrophoresis. Sequencing reactions using T3 primer
Were conducted on the ampli?ed cDNAs to provide a prelimi

branes by semidry electrophoretic transfer in Tris-glycine

60

in 2.5% formalin-PBS/0.01% glutaraldehyde and permeabi

The SnSAG1 open reading frame Without the predicted

liZed With 0.2% TritonX-100. After incubation With primary
antibody, the slides Were rinsed, then incubated With ?uores

amino-terminal signal peptide and the carboxyl-terminal

cein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG

clonal Antiserum

hydrophobic tail Was ampli?ed by PCR from the pSnAg8
cDNA using primers that introduce a NdeI restriction site
prior to base 45 (numbered from the initiation codon) and an
XhoI site after base 743. The ampli?cation product Was

65

(Jackson Immunoresearch Labs, Inc.). The slides Were
mounted in Vectashield With DAPJ (Vector Laboratories,
Inc.) and examined With a Zeiss axioscope equipped for epi

?uorescence microscopy.
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Results

by the invention and set forth herein have been derived in a
fashion similar to that set forth above for SnSAGl. These
novel nucleotide sequences and protein sequences of Sarco
cyslis neurona can be utiliZed in the production of vaccines

Isolation and Analysis of Immunoreactive cDNA Clones
A primary screen of the cSn.1 cDNA library identi?ed
multiple immunoreactive phage plaques, and a total of 25
plaques Were isolated and resuspended in SM buffer. Ampli
?cation of the cDNA inserts With T3 and T7 oligonucleotides
revealed that 22 of the phage clones had similar lengths of

and/or antigen/ antibody kits for prevention and diagnosis of
Sarcocyslis neurona infection. One preferred embodiment of
the invention is a vaccine comprised of an alpha virus expres
sion vector and nucleic acid selected from the nucleic acid
sequences disclosed herein.
Identi?cation of S. neurona Surface Antigens and Expression

approximately 1500 base pairs (bp), and sequence analysis
using T3 primer indicated that these 22 cDNAs represent the
same gene. A secondary screen Was performed on ?ve of the

as Recombinant Proteins

selected cDNAs, and tWo highly reactive phage clones, des
ignated SnAgI.8 and SnAgI.9, Were chosen for further analy

Analysis of the S. neurona EST database revealed four
paralogous proteins that are homologous to the SAG and SRS
surface antigens of Toxoplasma gondii. Each S. neurona gene

ses.

To obtain a preliminary identi?cation of the parasite pro
tein encoded by the selected cDNAs, the SnAgI.9 clone Was
used to a?inity purify antibodies that bind the antigen
expressed by this clone, and the eluted antibodies Were used

Was predicted to encode a protein that possessed an amino

terrninal signal peptide and a carboxyl-terminal glycolipid
anchor site, consistent With the proteins being surface anti
gens. Because of their similarity to Toxoplasma SAGs and
their probable surface display on meroZoites, the four S. neu

to probe a Western blot of S. neurona meroZoite lysate. As

shoWn in FIG. 1, the puri?ed antibodies reacted With an
approximately 31-kDa antigen in reduced S. neurona lysate.

20

rona proteins Were designated SnSAGl, SnSAG2, SnSAG3,
and SnSAG4. The four putative surface antigens Were each
expressed as a recombinant protein in E. coli, and these Were
used to immuniZe rabbits and rats for monospeci?c poly

25

Were used in Western blot analysis of reduced (With 2-mer
captoethanol) S. neurona lysate to reveal each of the SnSAGs
(See, FIG. 3). The mature forms of native SnSAGl and
SnSAG4 are predicted to be approximately 24 kDa, but these
antigens co-migrated at approximately 30-32 kDa and corre
spond to the immunodominant antigen Sn30 that has been

Furthermore, the antigen revealed by the phage-puri?ed anti
bodies comigrated With a protein that is recogniZed by equine
or rabbit antisera against S. neurona as the major immun

odominant antigen of this parasite (FIG. 1, lanes 2 and 3).

clonal antisera production. The resulting polyclonal antisera

This result implies that the 22 matching cDNA clones isolated

during the library screen and represented by SnAgI.8 and
SnAgI.9 encode the immunodominant antigen of S. neurona.
Full-length sequence analysis of SnAgI.8 revealed a cDNA
insert of 1493 nucleotides, With an open reading frame (ORF)
that encodes a 276 amino acid protein. Sequence analysis of
SnAgI.9 indicated that this clone Was virtually identical to

30

described previously (See, FIG. 3) (Granstrom et al., 1993;
Liang et al., 1998). SnSAGl has also been identi?ed by others

SnAgI.8, although its 3' untranslated region (UTR) Was
35

as a major surface antigen matching the immunodominant
Sn30 band (Ellison et al., 2002), but it is apparent that
SnSAG4 likely contributes to the antibody reactivity at this
molecular Weight. The mature form of SnSAG2 is predicted
to be about 12 kDa, but this antigen migrated at approxi

40

mately 18-19 kDa and corresponds to the previously
described immunodominant Sn16 antigen (See, FIG. 3)
(Granstrom et al., 1993; Liang et al., 1998). Mature SnSAG3
is predicted to be 23 kDa, but migrated at about 28 kDa (See,
FIG. 3). The aberrant migration of the SnSAGs under reduc

45

viously for the surface antigens of both T gondii (Burg et al.,
1988; Cesbron-DelauW et al., 1994) andN. caninum (HoWe et
al., 1998). Importantly, the Western blot experiments demon

approximately 160 nucleotides longer due to an alternative

polyadenylation site. A hydrophobicity plot of the encoded
protein shoWed hydrophobic domains at both termini, Which
correspond to a predicted signal peptide at the amino termi
nus and a GPI anchor addition sequence at the carboxyl

terminus (data not shoWn). The signal peptide cleavage is
predicted to occur at Alals-Argl6 (SignalP; [Nielsen, 1997
#2047], and the most likely GPI transamidase cleavage site is
predicted to be at Ala247-Asn248 (DGPI; SWiss Institute of
Bioinformatics). A single N-glycosylation site Was predicted
at residues 140-143. Removal of the N-terminal and C-termi
nal signal sequences results in a mature protein of 242 amino
acids that has a predicted molecular Weight of 24.2 kDa

ing conditions is a characteristic that has been observed pre

before any potential post-translational modi?cations (e.g.,

strated that the recombinant forms of the SnSAGs are recog

glycolipid anchor addition, glycosylation).
To identify homology to previously characteriZed
sequences, BLAST searches [Altschul, 1990 #616] of the
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non-redundant GenBank databases Were conducted With the

sis of complete parasite antigen (i.e., S. neurona meroZoite

SnAgI.8 coding sequence as the query. These searches
revealed a statistically signi?cant similarity to the 31 kDa

major surface antigen of Sarcocyslis muris [Eschenbacher,
1992 #1767] and a less signi?cant but recogniZable similarity
to several SAG2-related surface antigens from T gondii [Le
kutis, 2000 #2049] . (FIG. 2). In conjunction With the Western
blot analysis and the predictions of a signal peptide and a
GPI-anchor addition, these results suggested that the gene
represented by the SnAgI.8 and SnAgI.9 cDNAs encodes an
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quently, We tentatively designated this protein SnSAGl, fol
loWing the genetic nomenclature that is utiliZed for the related

SnSAG4 as Well as for the SnGF Cluster sequences provided

lysate). Similar results Were obtained With rSnSAG2, rSn
SAG3, and rSnSAG4. These data demonstrate the utility of
using the rSnSAGs in ELISA formats to monitor antibody
responses in S. neurona-infected horses.

Enzyme-Linked Immunosorbent Assays (ELISAs) Based on

immunodominant surface antigen of S. neurona; conse

apicomplexan parasites T gondii and N. caninum [Sibley,
1991 #13; HoWe, 1999 #1759].
The sequence analysis for SnSAG2, SnSAG3, and

niZed by antibodies from S. neurona-infected horses. There is
strong concordance betWeen antibody recognition of recom
binant SnSAGl (rSnSAGl) and standard Western blot analy
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Recombinant S. neurona Surface Antigens (rSnSAGs)
The rSnSAGs expressed in E. coli have been shoWn in
Western blots to be recogniZed by equine antibodies; conse
quently, these recombinant antigens can be utiliZed as the key
reagents for developing ELISAs based on single S. neurona
antigens. An ELISA test Was developed for each of the four
rSnSAGs that have been identi?ed by the invention.
Expression and Puri?cation of Recombinant SnSAGs.

To produce highly puri?ed recombinant forms of the
SnSAGs, the genes for each antigen Were cloned into the
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pET22b expression plasmid from Novagen (Madison, Wis).
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This plasmid vector provides a carboxyl-terminal fusion to a

(Pierce) and exposed to radiographic ?lm or documented
With a FluorChem 8800 imaging system (Alpha lnnotech

6-residue oligohistidine domain (His-Tag), Which binds to

Corp.).
For rSnSAS ELlSAs, high-binding 96-Well plates (Com

metal ion a?inity columns and alloWs for the ef?cient one

step puri?cation of the expressed recombinant protein. Plas

ing) Were incubated overnight at 40 C. With 100 pl puri?ed

mid constructs Were transformed into BL21 DE3) host cells

rSnSAGl, rSnSAG2, rSnSAG3, or rSnSAG4 diluted to 0.20

(CodonPlus, Stratagene, lnc .), and expression of recombinant

pg/ml, 1.00 pg/ml, 0.09 pg/ml, and 0.21 pg/ml, respectively.

protein Was induced by addition of IPTG. Bacterial clones
that reliably expressed the recombinant SnSAGs Were

The plates Were rinsed With PBS/0.05% TWeen 20 and
blocked for 1.5 h at room temperature With PBS/ 1% TWeen

20/ 0.5% normal goat serum/ 0.001 g/ml nonfat dry milk. Pri

selected and cyropreserved for future study. The recombinant
S. neurona surface antigens have been designated rSnSAGl,
rSnSAG2, rSnSAG3, and rSnSAG4.
To obtain recombinant protein, the appropriate bacterial
clone Was grown to logarithmic phase in LB medium, and
protein expression Was induced by addition of IPTG to the

mary sera or CSF Was diluted With PBS/ 1% TWeen 20/0.5%

normal goat serum/0.001 g/ml nonfat dry milk. One hundred
pl aliquots of the sera or CSF containing mixed antibody
populations Were added to duplicate Wells and incubated for
2 h at room temperature. The Wells Were rinsed, and then
incubated for 2 h at room temperature With 150 pl of horse

culture. The recombinant protein Was extracted from inclu
sion bodies With 6 M urea and puri?ed from the host cell

lysate by Ni++-column chromatography according to the
manufacturer’s protocol (His-Bind resin and buffers,

radish peroxidase-conjugated goat anti-horse immunoglobu
lin G (IgG) secondary antibody (Jackson lmmunoResearch
20

Novagen). Urea Was removed by dialysis. If necessary,
recombinant proteins Was concentrated by centrifugal ultra
?ltration in Centricon-10 columns (Amicon).

ELISA Assay

o-phenylenediamine dihydrochloride (Sigma) at 0.4 mg/ml
(200 pl) Was added. After 10 min incubation, the reaction Was
25

The SN3 strain of S. neurona and the Oregon strain of

Neospora hughesi Were maintained by serial passage in
bovine turbinate cell monolayers. Upon lysis of the host cell
monolayer, Zoites Were dispersed and ?ltered (3 .0 pm Nucle
opore membrane ?lter, Whatman) to remove debris. Har
vested parasites Were counted, Washed, and stored at —200 C.

30

Concentration of puri?ed recombinant proteins prepared
35

rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4 Were diluted
in buffer (0.5 M NaCl and 20 mM Tris-HCl) Without urea to

pg/ml, and 10.3 pg/ml, respectively.
horses With histologically con?rmed EPM. The negative con
trol sample for all assays Was a preinfection serum sample
from a Weanling used in an experimental infection trial.
Thirty six equine serum samples submitted for S. neurona
serology testing Were used for standardization of the rSnSAG
ELlSAs. The samples had previously been classi?ed as posi

25 of 26 (96.2%) EPM-con?rmed horses (see FIG. 6). The
rSnSAG2 and rSnSAG3 ELlSAs yielded seropositive results
in 24 of26 (92.3%) EPM-con?rmed horses. Only 18 ofthe 26
(69.2%) horses had detectable serum antibody titers against
rSnSAGl. In total, 18 (81.8%), 18 (81.8%), 20 (90.0%), and
21 (95.5%) of the 22 CSF samples had detectable antibody

titers against rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4,
respectively (see FIG. 7). No signi?cant cross-reactivity of
the ELlSAs Was found When tested against samples contain
ing antibodies to tWo related pathogens, S. fayeri and S.

?nal protein concentrations of 8.15 pg/ml, 23.0 pg/ml, 14.56
Positive control serum samples Were obtained from tWo

stopped With 50 pl of 3 M H2SO4, and OD490 Was measured
in an Emax microplate reader (Molecular Devices). To account
for interplate variation, the OD of each sample Was expressed
as a percentage of the high positive standard on the plate.
Serum antibody titers against rSnSAG4 Were detected in

as described above Was determined by a calorimetric assay

(Coomassie Plus Protein Assay Reagent, Pierce). Puri?ed

Laboratories, Inc.) diluted to 1:10,000 in PBS/ 1% TWeen
20/0.5% normal goat serum/0.001 g/ml nonfat dry milk. The
Wells Were then again rinsed. The chromogenic substrate

hughesi (data not shoWn).
40
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Expression of Recombinant S. neurona Surface Antigens
(rSnSAGs) in Mammalian Cells
The open reading frame of each SnSAG as previously
described Was directionally cloned into the Kpnl and Xbal
restriction sites of the pVAXl DNA vaccine plasmid vector

(lnvitrogen), and the ?delity of the pVAXzSnSAG plasmid

tive or negative by Western blot. TWenty-seven samples from

constructs Was con?rmed by expression in COS-1 (green

horses of con?rmed EPM status Were obtained from a collec

monkey kidney) cells With (+GPl) and Without (—GPI) the

tion of the University of Kentucky Gluck Equine Research
Center. All cases Were con?rmed by histological examination
of central nervous system tissues for the presence of lesions
consistent With EPM, as Well as Western blot analysis of CSF
?uids. Three equine serum samples from an S. fayeri chal
lenge trial Were used to examine assay cross-reactivity. An N.
hughesi positive control serum sample Was also evaluated.
Native and recombinant proteins Were suspended in SD
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cells using the cationic lipid reagent Lipofectamine 2000
(lnvitrogen). At 48 hr post-transfection, the coverslips Were
removed and the cells Were ?xed With formalin. The cells
Were then labeled With an anti-rabbit SnSAG serum as appro
55

priate, folloWed by goat anti-rabbit antibody conjugated to
?uorescein isothiocyanate (FITC). Cell nuclei Were labeled
With DAPI for contrast. As shoWn in FIG. 8, mammalian cells

S-PAGE buffer supplemented With protease inhibitor cocktail
(Sigma) and separated on 12% polyacrylamide gels. For

clearly expressed each transfected surface antigen (SnSAGl,
SnSAG2, SnSAG3, and SnSAG4).

Western blot proteins Were transferred to nitrocellulose mem

branes by semi-dry electrophoresis. Membranes Were
blocked With PBS containing nonfat dry milk, 0.1% TWeen

GPI anchor. Cells Were groWn on coverslips in 24-Well plates.
The pVAX: SnSAG plasmids Were transfected into the COS-1
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Accordingly, a simple, reliable assay is provided for detec
tion of S. neurona infection. lmportantly, the assays did not

20, and 5% normal goat serum, and incubated for 1 hour in

cross-react With antisera against related pathogens. The assay

primary antibody solution. The membranes Were Washed,
folloWed by incubation for 45 min. With horseradish peroxi

described herein provides numerous advantages over current

dase-conjugated secondary antibodies (Jackson lmmunoRe
search Laboratories, Inc.). Membranes Were processed for
chemiluminescent detection using SuperSignal substrate
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serologic assays, including ease of use, high sample through
put, and more objective interpretation of results. Further, the
use of recombinant S. neurona surface antigens obviates the

need to propagate parasites in tissue culture. Relative to

